01.08.2017
- AstraZeneca has entered into a global collaboration with US drugmaker Merck to develop and commercialize the former’s investigational cancer treatments Lynparza (olaparib) and...
21.02.2017
- AstraZeneca has agreed to sell the commercial rights for its cancer treatment Zoladex in the US and Canada for $250 million upfront to private equity-backed TerSera Therapeutics –...
